Toll-like receptors regulate B cell cytokine production in patients with diabetes

Diabetologia

Volumn 53, Issue 7, 2010, Pages 1461-1471

  Jagannathan, M ^a   McDonnell, M ^b   Liang, Y ^b   Hasturk, H ^c   Hetzel, J ^b   Rubin, D ^b   Kantarci, A ^c   Van Dyke, T E ^c   Ganley Leal, L M ^b   Nikolajczyk, B S ^d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY   (United States)

^d NONE

Author keywords

B lymphocytes; Cytokines; Diabetes mellitus; Human; Toll like receptors

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 8; TOLL LIKE RECEPTOR;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETES MELLITUS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; MALE; PERIODONTAL DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADULT; AGED; B-LYMPHOCYTES; CYTOKINES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-10; INTERLEUKIN-8; MALE; MIDDLE AGED; TOLL-LIKE RECEPTORS;

EID: 77955653584     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-010-1730-z     Document Type: Article

References (48)

1. King GL (2008) The role of inflammatory cytokines in diabetes and its complications. J Periodontol 79:1527-1534.
2. Duncan BB, Schmidt MI, Pankow JS et al (2003) Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52:1799-1805.
3. Spranger J, Kroke A, Mohlig M et al (2003) Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52:812-817.
4. Creely SJ, McTernan PG, Kusminski CM et al (2007) Lipopoly-saccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 292:E740-E747.
5. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116:3015-3025.
6. Page RC (1991) The role of inflammatory mediators in the pathogenesis of periodontal disease. J Periodontal Res 26:230-242.
7. Poggi M, Bastelica D, Gual P et al (2007) C3H/HeJ mice carrying a Toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia 50:1267-1276.
8. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB et al (2007) Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 56:1986-1998.
9. Caricilli AM, Nascimento PH, Pauli JR et al (2008) Inhibition of toll-like receptor 2 expression improves insulin sensitivity and signaling in muscle and white adipose tissue of mice fed a high-fat diet. J Endocrinol 199:399-406.
10. Bagarolli RA, Saad MJ, Saad ST (2010) Toll-like receptor 4 and inducible nitric oxide synthase gene polymorphisms are associated with type 2 diabetes. J Diabetes Complications. doi:10.1016/j.jdiacomp.2009.03.003.
11. Kolz M, Baumert J, Muller M et al (2008) Association between variations in the TLR4 gene and incident type 2 diabetes is modified by the ratio of total cholesterol to HDL-cholesterol. BMC Med Genet 9:9.
12. Park Y, Park S, Yoo E, Kim D, Shin H (2004) Association of the polymorphism for Toll-like receptor 2 with type 1 diabetes susceptibility. Ann N Y Acad Sci 1037:170-174.
13. Jagannathan M, Hasturk H, Liang Yet al (2009) Toll-like receptor cross talk specifically regulates cytokine production by B cells from chronic inflammatory disease patients. J Immunol 183:7461-7470.
14. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A (2002) Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416:603-607.
15. Bourke E, Bosisio D, Golay J, Polentarutti N, Mantovani A (2003) The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 102:956-963.
16. Hornung V, Rothenfusser S, Britsch S et al (2002) Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168:4531-4537.
17. Duddy ME, Alter A, Bar-Or A (2004) Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 172:3422-3427.
18. Hanten JA, Vasilakos JP, Riter CL et al (2008) Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol 9:39.
19. Shin H, Zhang Y, Jagannathan M et al (2009) B cells from periodontal disease patients express surface Toll-like receptor 4. J Leukoc Biol 85:648-655.
20. Noronha AM, Liang Y, Hetzel JT et al (2009) Hyperactivated B cells in human inflammatory bowel disease. J Leukoc Biol 86:1007-1016.
21. Duddy M, Niino M, Adatia F et al (2007) Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 178:6092-6099.
22. Blair PA, Norena LY, Flores-Borja F et al (2010) CD19(+)CD24 (hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32:129-140.
23. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM (2002) B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3:944-950.
24. Mauri C, Feldmann M, Williams RO (2003) Down-regulation of Th1-mediated pathology in experimental arthritis by stimulation of the Th2 arm of the immune response. Arthritis Rheum 48:839-845.
25. van Exel E, Gussekloo J, de Craen AJ, Frolich M, Bootsma-Van Der Wiel A, Westendorp RG (2002) Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 51:1088-1092.
26. Lampropoulou V, Hoehlig K, Roch T et al (2008) TLR-activated B cells suppress T cell-mediated autoimmunity. J Immunol 180:4763-4773.
27. Mealey BL, Ocampo GL (2007) Diabetes mellitus and periodontal disease. Periodontol 2000 44:127-153.
28. Freeman DJ, Norrie J, Caslake MJ et al (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51:1596-1600.
29. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW (2004) C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110:380-385.
30. Armitage GC (1999) Development of a classification system for periodontal diseases and conditions. Ann Periodontol 4:1-6.
31. Golenbock DT, Hampton RY, Qureshi N, Takayama K, Raetz CR (1991) Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J Biol Chem 266:19490-19498.
32. Rao S, Procko E, Shannon MF (2001) Chromatin remodeling, measured by a novel real-time polymerase chain reaction assay, across the proximal promoter region of the IL-2 gene. J Immunol 167:4494-4503.
33. Ganley-Leal LM, Liu X, Wetzler LM (2006) Toll-like receptor 2-mediated human B cell differentiation. Clin Immunol 120:272-284.
34. Dasu MR, Devaraj S, Park S, Jialal I (2010) Increased Toll-like receptor activation and TLR ligands in recently diagnosed type 2 diabetes subjects. Diabetes Care. doi:10.2337/dc09-1799.
35. Marks DJ, Harbord MW, MacAllister R et al (2006) Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 367:668-678.
36. Darveau RP, Pham TT, Lemley K et al (2004) Porphyromonas gingivalis lipopolysaccharide contains multiple lipid A species that functionally interact with both toll-like receptors 2 and 4. Infect Immun 72:5041-5051.
37. Senn JJ (2006) Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J Biol Chem 281:26865-26875.
38. Winer S, Chan Y, Paltser G et al (2009) Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 15:921-929.
39. Feuerer M, Herrero L, Cipolletta D et al (2009) Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 15:930-939.
40. Nishimura S, Manabe I, Nagasaki M et al (2009) CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 15:914-920.
41. Herder C, Haastert B, Muller-Scholze S et al (2005) Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 54(Suppl 2):S11-S17.
42. Fain JN (2006) Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 74:443-477.
43. Qi X, Li J, Gu J, Li S, Dang Y, Wang T (2003) Plasma levels of IL-8 predict early complications in patients with coronary heart disease after percutaneous coronary intervention. Jpn Heart J 44:451-461.
44. Bruun JM, Pedersen SB, Richelsen B (2000) Interleukin-8 production in human adipose tissue. inhibitory effects of anti-diabetic compounds, the thiazolidinedione ciglitazone and the biguanide metformin. Horm Metab Res 32:537-541.
45. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610-614.
46. Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517-1526.
47. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R (1996) Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881-885.
48. Yazdani-Biuki B, Stelzl H, Brezinschek HP et al (2004) Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur J Clin Invest 34:641-642.